The patient was discharged with alleviated jaundice and significantly improved liver function indexes after 1 month of symptomatic treatments. Maintenance treatments with oral UDCA (50 mg/day), compound glycyrrhizin (12.5 mg/day), and fat-soluble vitamins (vitamin AD, 1800 U/day; vitamin E, 25 mg/day) were recommended to be continued further after discharge from the hospital. During the recent 9-month follow-up period, he had complete clinical and biochemical recovery except for slightly elevated levels of AST and TBA (Table 1). At this writing, he is 1 year old and remains stable with a normal growth (weight, 8,750 g; height, 74 cm) after drug withdrawal for 3 months. He can walk with the help of an instrument, and no sign of bone fragility was observed. His language development is normal, and repeated hearing testing was unremarkable.
o2he, unc45a, case report, cholestasis, compound heterozygote variants